TPCW
EW icon

TD Private Client Wealth’s Edwards Lifesciences EW Stock Holding History

TD Private Client Wealth’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Sell
2,320
-110
-5% -$9.21K ﹤0.01% 662
2026
Q1 		$195K Buy
2,430
+285
+13% +$23.5K ﹤0.01% 653
2025
Q4 		$183K Sell
2,145
-133
-6% -$10.9K ﹤0.01% 679
2025
Q3 		$177K Buy
2,278
+122
+6% +$9.53K ﹤0.01% 679
2025
Q2 		$169K Buy
+2,156
New +$161K ﹤0.01% 672
2025
Q1 		– Sell
-2,137
Closed -$158K – 1439
2024
Q4 		$158K Sell
2,137
-1,209
-36% -$84.6K ﹤0.01% 647
2024
Q3 		$221K Sell
3,346
-17,777
-84% -$1.29M 0.01% 581
2024
Q2 		$1.95M Sell
21,123
-1,583
-7% -$140K 0.06% 238
2024
Q1 		$2.17M Sell
22,706
-1,514
-6% -$127K 0.07% 220
2023
Q4 		$1.85M Buy
24,220
+8,064
+50% +$561K 0.07% 234
2023
Q3 		$1.12M Buy
16,156
+274
+2% +$22K 0.05% 304
2023
Q2 		$1.5M Buy
15,882
+1,242
+8% +$108K 0.06% 266
2023
Q1 		$1.21M Buy
14,640
+220
+2% +$17.3K 0.05% 295
2022
Q4 		$1.08M Sell
14,420
-14,001
-49% -$1.08M 0.05% 313
2022
Q3 		$2.35M Sell
28,421
-609
-2% -$58.6K 0.12% 177
2022
Q2 		$2.77M Sell
29,030
-145
-0.5% -$15K 0.13% 161
2022
Q1 		$3.43M Buy
29,175
+3,158
+12% +$354K 0.15% 151
2021
Q4 		$3.37M Sell
26,017
-4,029
-13% -$470K 0.14% 161
2021
Q3 		$3.4M Buy
30,046
+16,956
+130% +$1.94M 0.15% 156
2021
Q2 		$1.36M Buy
13,090
+312
+2% +$29.4K 0.06% 295
2021
Q1 		$1.07M Buy
12,778
+1,097
+9% +$92.7K 0.05% 307
2020
Q4 		$1.07M Buy
11,681
+1,460
+14% +$121K 0.05% 292
2020
Q3 		$816K Sell
10,221
-907
-8% -$70.8K 0.05% 310
2020
Q2 		$769K Buy
11,128
+3,406
+44% +$242K 0.04% 312
2020
Q1 		$486K Sell
7,722
-1,194
-13% -$86.1K 0.03% 325
2019
Q4 		$693K Buy
+8,916
New +$696K 0.04% 310

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

TD Private Client Wealth's EW Position: Q2 2026 in Review

TD Private Client Wealth reduced its Edwards Lifesciences (EW) stake by 4.5% in Q2 2026, selling an estimated $9.21K and leaving 2,320 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #662.

TD Private Client Wealth first reported a position in EW in Q4 2019 and has held it in 26 quarters since. The position peaked at $3.43M in Q1 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • TD Private Client Wealth held 2,320 shares of Edwards Lifesciences worth $210K as of Q2 2026.
  • TD Private Client Wealth sold 110 Edwards Lifesciences shares in Q2 2026, an estimated $9.21K.
  • Edwards Lifesciences made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #662 holding.
  • TD Private Client Wealth first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 26 quarters since.
  • TD Private Client Wealth's Edwards Lifesciences position peaked at $3.43M in Q1 2022.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.